Parkinson’s disease: Servier and Oncodesign announce the selection of a preclinical candidate
Initiated in March 2019, this Research and Development partnership is focused on the identification of LRRK2 kinase inhibitors derived from Oncodesign’s proprietary Nanocyclix® platform and their potential to act as therapeutic agents against Parkinson’s disease, drawing on Servier and Oncodesign’s complementary expertise in the field of neurodegenerative disease and kinase inhibitors.
Progress in molecular biology enabled the identification of oncogenes and tumor suppressor genes translated into targeted therapies, aiming to disrupt specific pathways necessary for efficient cancer cell proliferation and survival. For this targeting, specific antibodies were designed, along with chemical compounds, revealing the potency of opsonization and the role of immune cytotoxic cells in the elimination of cancer cells.
Recently, the identification of immuno-suppressive cells has shown the pivotal role of immune system in cancer progression,. The identification of key proteins such as PD-1 and CTLA-4 which regulate the immune response have enabled the development of antibodies unblocking CD8 T cell repression to eliminate cancer cells. Different strategies involving immune molecules and/or immune cells are have now been developed, such as ADCs, bi-specific antibodies or CAR-T cells.
Most cancer vaccination therapies currently validated for clinical use are prophylactic, aiming to eliminate viruses, such as HPV or HBV. We will present models that provide useful insights into the evaluation of these preventive vaccinations.
Furthermore, several promising strategies for therapeutic vaccinations are gaining increasing interest. More recent vaccines are issueof high throughput sequencing innovations, allowing the identification of neo-antigens, which are a consequence of the high mutation rate of cancer cells. The exponential growth of genomic capabilities may even enable personalized vaccination.
The low response to therapeutic vaccines most often observed in experiments could be enhanced by direct (like anti-PD1) or indirect (adjuvant, oncolytic virus) immune-stimulation.
In this webinar, we discuss the different strategies that might help to investigate all kinds of vaccination, from in vitro assays to humanized mice, alone or combined with other treatments.
Key learning objectives
Introduction to cancer vaccine
How can Oncodesign support evaluation of cancer vaccine
Discover our speaker Dr. Guillaume Serin
Guillaume SERIN obtained his Ph.D. in 1998 in the University of Toulouse, France, in study of ribosome biogenesis, followed by post-doctoral position at the Roswell Park Cancer Institute in Buffalo, USA, to characterize new proteins involved in the quality control of mRNA. Guillaume joined Oncodesign in 2002 to transfer his skills in molecular and cellular biology to the Cellular Pharmacology lab through different European collaborative programs and internal drug discovery. For the past few years, he is fully involved as Study Director in helping our clients to develop in vitro and in vivo preclinical studies covering different aspects of anticancer therapy including vaccination.